Ignyta, Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.
The company stated in the following press release that they conduct pre-clinical trials of their drugs on animals.
Entrectinib has demonstrated in vivo antitumor activity against various TrkA, ROS1 or ALK-driven mouse xenograft models of different human cancers, and has demonstrated oral bioavailability and been observed to efficiently cross the blood brain barrier in three animal species. Read the following article
Ignyta, Inc. is a precision oncology biotechnology company that engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. It plans focus on two product candidates: entrectinib, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors ROS1 and ALK proteins, which is in two Phase I/II clinical studies in molecularly defined patient populations for the treatment of solid tumors; and RXDX-103, a development program targeting the cell division cycle 7-related, or CDC7, protein kinase. The company was founded by Jonathan E. Lim on October 31, 2013 and is headquartered in San Diego, CA. [Source: MarketWatch]
Company Website: https://ignyta.com